Men With Castrate Resistant Prostate Cancer Can Experience A PSA Flare When Starting Docetaxel Chemotherapy

The PSA flare phenomenon when first starting chemotherapy with docetaxel has been noted by many clinicians. To evaluate this flare in men with castrate resistant prostate cancer treated with docetaxel, researchers retrospectively evaluated the charts of 56 men who received docetaxel-based chemotherapy in three different centers from August 1999 to August 2007. They found that [...]

Degarelix Proves to be the Superior Hormone Deprivation Treatment (ADT) for Men with Advanced Prostate Cancer

Based on six recent retrospective analyses comparing the gonadotropin-releasing hormone (GnRH) antagonist degarelix against the traditional luteinizing hormone-releasing hormone (LHRH) agonists (i.e. Zoladex, Lupron etc.) men with advanced prostate cancer experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events. The six analyses compared data from randomized trials that [...]

Go to Top